{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:14:36Z","timestamp":1774008876175,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI14C2750"],"award-info":[{"award-number":["HI14C2750"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a first-in-human phase I study of tanibirumab in patients with solid tumors refractory to standard chemotherapy. Primary endpoints were evaluating safety, pharmacokinetics (PKs), estimating maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). <jats:italic>Methods<\/jats:italic> We designed our study to escalate tanibirumab at 9 different dose levels with a 3\u00a0+\u00a03 method and tanibirumab (1\u201328\u00a0mg\/kg) was administered intravenously on D1, 8, 15 in 28-day courses. Dose limiting toxicities (DLTs) were only assessed during the first cycle of treatment and response evaluation was performed every 2\u00a0cycles. The effects of tanibirumab on several angiogenic factors were analyzed. <jats:italic>Results<\/jats:italic> From October 2011 to September 2013, a total of 26 patients with refractory solid tumors were enrolled. The median age was 58\u00a0years (range, 27\u201375) and 20 patients were male. The most common tumor type was colorectal cancer (<jats:italic>N<\/jats:italic>\u00a0=\u00a019) and seven patients had a history of previous bevacizumab treatment. As hemangioma continued to occur, the final dose level, 28\u00a0mg\/kg, was not performed. DLTs were not found, and the MTD was confirmed to be 24\u00a0mg\/kg. Hemangioma was observed in 16 patients (61.5%), but all were grade 1\u20132 and disappeared after discontinuation of the study drug. Among the 18 patients in the efficacy set, no objective response was observed, but 11 patients showed stable disease. PKs were characterized by dose-dependent linear exposure and the mean trough concentrations exceeded biologically relevant target levels at 12\u00a0mg\/kg and above. Serum VEGF, soluble VEGFR-2, and PlGF increased at the 4\u00a0mg\/kg dose level and above. <jats:italic>Conclusions<\/jats:italic> Treatment with tanibirumab showed a tolerable toxicity profile and modest clinical efficacy in patients with refractory solid tumors. A phase II trial of tanibirumab is ongoing now.<\/jats:p>","DOI":"10.1007\/s10637-017-0463-y","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T04:05:07Z","timestamp":1491624307000},"page":"782-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors"],"prefix":"10.1007","volume":"35","author":[{"given":"Su Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weon Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin San","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,8]]},"reference":[{"key":"463_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273\u2013286. doi:10.1038\/nrd2115","journal-title":"Nat Rev Drug Discov"},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795\u2013803. doi:10.1038\/nrc909","journal-title":"Nat Rev Cancer"},{"key":"463_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0958-1669(00)00153-1","volume":"11","author":"N Ferrara","year":"2000","unstructured":"Ferrara N (2000) VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617\u2013624. doi:10.1016\/S0958-1669(00)00153-1","journal-title":"Curr Opin Biotechnol"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative Oncology group study E3200. J Clin Oncol 25:1539\u20131544. doi:10.1200\/jco.2006.09.6305","journal-title":"J Clin Oncol"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326\u20135334. doi:10.1200\/jco.2008.16.3212","journal-title":"J Clin Oncol"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342. doi:10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842\u20131847. doi:10.1093\/annonc\/mdp233","journal-title":"Ann Oncol"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. doi:10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"463_CR9","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1200\/JCO.2014.57.6231","volume":"32","author":"F Tomao","year":"2014","unstructured":"Tomao F, Tomao S, Benedetti Panici P (2014) Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial. J Clin Oncol 32:3580. doi:10.1200\/jco.2014.57.6231","journal-title":"J Clin Oncol"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334. doi:10.1016\/s1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"463_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. doi:10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"463_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124. doi:10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"463_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516\u20132524. doi:10.1001\/jama.295.21.2516","journal-title":"JAMA"},{"key":"463_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339. doi:10.1016\/s0140-6736(13)61719-5","journal-title":"Lancet"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. doi:10.1016\/s1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12272-011-0821-9","volume":"34","author":"SH Lee","year":"2011","unstructured":"Lee SH (2011) Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 34:1223\u20131226. doi:10.1007\/s12272-011-0821-9","journal-title":"Arch Pharm Res"},{"key":"463_CR17","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","volume":"19","author":"AX Zhu","year":"2013","unstructured":"Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K (2013) A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19:6614\u20136623. doi:10.1158\/1078-0432.ccr-13-1442","journal-title":"Clin Cancer Res"},{"key":"463_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324. doi:10.1200\/jco.2005.02.2574","journal-title":"J Clin Oncol"},{"key":"463_CR19","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","volume":"23","author":"CG Willett","year":"2005","unstructured":"Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136\u20138139. doi:10.1200\/jco.2005.02.5635","journal-title":"J Clin Oncol"},{"key":"463_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780\u2013787. doi:10.1200\/jco.2009.23.7537","journal-title":"J Clin Oncol"},{"key":"463_CR21","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jaad.2004.01.033","volume":"51","author":"AN Haggstrom","year":"2004","unstructured":"Haggstrom AN, Frieden IJ (2004) Hemangiomas: past, present, and future. J Am Acad Dermatol 51:S50\u2013S52. doi:10.1016\/j.jaad.2004.01.033","journal-title":"J Am Acad Dermatol"},{"key":"463_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1525-1470.2005.00102.x","volume":"22","author":"IJ Frieden","year":"2005","unstructured":"Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon MC, Nopper AJ, Siegel DH, Mathes EW, Goddard DS, Bischoff J, North PE, Esterly NB (2005) Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 22:383\u2013406. doi:10.1111\/j.1525-1470.2005.00102.x","journal-title":"Pediatr Dermatol"},{"key":"463_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nm.1877","volume":"14","author":"M Jinnin","year":"2008","unstructured":"Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14:1236\u20131246. doi:10.1038\/nm.1877","journal-title":"Nat Med"},{"key":"463_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm1108-1147","volume":"14","author":"L Claesson-Welsh","year":"2008","unstructured":"Claesson-Welsh L (2008) Healing hemangiomas. Nat Med 14:1147\u20131148. doi:10.1038\/nm1108-1147","journal-title":"Nat Med"},{"key":"463_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/fon.10.75","volume":"6","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Mulder KE, Mackey JR (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 6:1085\u20131094. doi:10.2217\/fon.10.75","journal-title":"Future Oncol"},{"key":"463_CR26","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1158\/1078-0432.CCR-07-1550","volume":"13","author":"NC Ton","year":"2007","unstructured":"Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC (2007) Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 13:7113\u20137118. doi:10.1158\/1078-0432.ccr-07-1550","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0463-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:09:40Z","timestamp":1678511380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0463-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,8]]},"assertion":[{"value":"19 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board at Samsung Medical Center and registered in  NCT#01660360.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}